Ticker brief
PALI
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
14
authors 14d
9
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-29 → 2026-07-01 · now +0.45 (−1 bearish … +1 bullish)
Who spoke9
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -0.75 | 5 | +0.43 |
| @BiopharmIQ | B | · | 2 | +0.47 |
| @wallstengine | B | +0.82 | 1 | +0.55 |
| @CrweWorld | C | · | 1 | +0.50 |
| @PersimmonTI | A | -0.32 | 1 | +0.50 |
| @Maximus_Holla | C | -0.48 | 1 | +0.40 |
| @OzmosiHealth | C | · | 1 | +0.50 |
| @AponiaAnalytics | B | +0.89 | 1 | +0.50 |
| @PrismMarketView | C | · | 1 | +0.50 |
Recent signals14of 14 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-01 | @semodough | +0.45 | B. Riley has EQ Buy $6 PT and PALI Buy $7 PT, with safety scare faded and FDA go-ahead noted. | · | tweet ↗ |
| 2026-06-30 | @PrismMarketView | +0.50 | PALI received FDA IND clearance to start Phase 2 trial. | · | tweet ↗ |
| 2026-06-30 | @semodough | +0.35 | Stifel frames PALI key question as clinical execution, with oral IBD MOAs emerging as important. | · | tweet ↗ |
| 2026-06-30 | @semodough | +0.60 | HCW says IND clearance removes execution gate for PALI, expects appreciation, Buy target $7. | · | tweet ↗ |
| 2026-06-29 | @BiopharmIQ | +0.50 | PALI up 17% tied to FDA IND clearance for PALI-2108 and Ph2 path. | · | tweet ↗ |
| 2026-06-29 | @semodough | +0.25 | Asks why PALI and EQ are not moving higher on ABVX strong data. | · | tweet ↗ |
| 2026-06-29 | @AponiaAnalytics | +0.50 | FDA cleared IND for PALI-2108, enabling Phase 2 UC trial. | · | tweet ↗ |
| 2026-06-29 | @BiopharmIQ | +0.45 | Biotech stock news list with percent moves and catalysts at open. | · | tweet ↗ |
| 2026-06-29 | @OzmosiHealth | +0.50 | Palisade receives FDA IND clearance for PALI-2108 and plans Phase 2 study. | · | tweet ↗ |
| 2026-06-29 | @Maximus_Holla | +0.40 | Author calls PALI comeback nice. | · | tweet ↗ |
| 2026-06-29 | @semodough | +0.50 | Palisade Bio received FDA IND clearance for PALI-2108 and plans Phase 2 ASCENTRA-UC study. | · | tweet ↗ |
| 2026-06-29 | @PersimmonTI | +0.50 | Palisade Bio received FDA IND clearance and plans Phase 2 study. | · | tweet ↗ |
| 2026-06-29 | @CrweWorld | +0.50 | Palisade Bio receives FDA clearance of IND and plans Phase 2 study. | · | tweet ↗ |
| 2026-06-29 | @wallstengine | +0.55 | FDA cleared PALI IND for PALI-2108 Phase 2 ulcerative colitis trial. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.